Abstract:ID 129061 Poster Board 491 Background: Brilaroxazine, a novel multimodal neuromodulator, belongs to a class of next-generation treatments for schizophrenia and comorbid conditions. It functions as a D 2/3/4 and 5-HT 1A/2A partial agonist and a 5 HT 2B/7 antagonist with binding affinity for 5-HT 2B > D 2 . It also mediates inflammatory cytokines. With defined efficacy, safety, and pharmacokinetics from clinical trials, it offers a differentiated profile over other antipsychotics. Brilaroxazine's development involved rats, mice, and dogs for nonclinical toxicological evaluations. This study evaluated the absorption, metabolism, and excretion of brilaroxazine in rats after a single 14 C-brilaroxazine dose to qualify rats as a suitable toxicology species. Methods: This study involved 12 male Sprague Dawley rats divided equally into three groups. These animals received a single [ 14 C]-brilaroxazine 20 mg/kg (200 mCi/kg) oral dose. Group 1 rats had a bile-duct cannula (BDC) surgically implanted for bile and feces collection. Group 2 rats had blood collected for metabolite evaluation. Group 3 rats had urine and feces collected to determine the mass balance. Maximal post-dose collection times for bile samples were 72 hours (Group 1), serial blood samples were 72 hours (Group 2), and urine and feces samples were 168 hours (Group 3). Sample analysis included liquid scintillation counting (LSC) or a combustion/ LSC combination (blood, plasma, and excreta), validated liquid chromatography–mass spectrometry/mass spectrometry (unlabeled brilaroxazine and RP5081 plasma concentrations), and mass spectral analysis or direct comparison with authentic standards for metabolite structures (brilaroxazine, and metabolite RP5081). Results: Bile or feces of BDC rats or intact rats were the predominant routes for dose radioactivity excretion. The percent of the administered dose recovered in Group 1 BDC rat bile, feces, and urine accounted for 79.52%, 13.02%, and 5.60%, respectively. Bile and urine in Group 3 intact rats showed at least 85% dose absorption, with 81.51% of the administered dose recovered in feces and 8.89% in urine. Brilaroxazine represented ~31% of the circulating radioactivity exposure with three primary metabolites- M641a (oxidation + glucuronidation), RP5081 (O-dealkylated acid), and M219 (N-[2,3-dichlorphenyl]-glycine)- accounting for ~29%,~16%, and ~16%, respectively. In Group 1 rat bile, the analysis did not detect brilaroxazine but identified M641a, accounting for 70% of the bile radioactivity or 56% of the dose. In Group 3 intact rat feces, the mono-hydroxylated compound, M465a, was the major metabolite, accounting for 86% of the fecal radioactivity or 71% of the dose. The gut microflora likely converted the glucuronide metabolite, M641a, observed in Group 1 rat bile, to the mono-hydroxylated metabolite M465a, which underwent fecal elimination in Group 3 rats. Glucuronidase hydrolysis of M641a, producing M465a in a near quantitative yield, confirmed this supposition. Conclusions: Following oral administration, brilaroxazine in rats underwent rapid absorption, extensive metabolism, and elimination via hepato-biliary excretion. The primary human metabolites, RP5081 and M219, were among the most commonly circulated in rats. Both humans and rats utilize 465a formation as the major metabolic pathway. These findings confirm that rats are a suitable rodent species for the toxicological evaluations of brilaroxazine. Reviva Pharmaceutical Holdings, Inc.

Metabolism and disposition of zamicastat in rats

Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double-blind, randomized, placebo-controlled study in healthy subjects

Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure

In Vitro Metabolism and Transport Characteristics of Zastaprazan

Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans

Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects

In Vitro Metabolism of Zolmitriptan in Rat Cytochromes Induced with Β-Naphthoflavone and the Interaction Between Six Drugs and Zolmitriptan

Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human

The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation

Pharmacokinetics and Metabolite Identification of a Novel VEGFR-2 and Src Dual Inhibitor 6-Chloro-2-methoxy-n-(2-methoxybenzyl) Acridin-9-amine in Rats by Liquid Chromatography Tandem Mass Spectrometry

Preclinical metabolism and disposition of [14C]GFH009, a novel selective CDK9 inhibitor

Metabolism characterization and toxicity of N-hydap, a marine candidate drug for lung cancer therapy by LC–MS method

Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects

Metabolism of tresperimus by rat aorta semicarbazide-sensitive amine oxidase (SSAO)

Absorption, Metabolism, and Excretion of Brilaroxazine in Rats

Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys

Insights into the Metabolism, Disposition, and Quantitative Profile of mGlu5 NAM AE90015 with Metabolite Identification and a Novel Integration Method

Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats.

Metabolism of Tanshinol Borneol Ester in Rat and Human Liver Microsomes